BioLineRx director Yan Shaoyu files Form 3

BioLineRx Ltd. director Yan Shaoyu has filed an initial Form 3 insider report.

Accepted by SEC EDGAR 04/10/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

BioLineRx Ltd. director Yan Shaoyu has filed an initial Form 3 insider report. The data shows no reported transactions, with buy, sell, acquire, and dispose counts all at zero. The filing also lists no derivative positions and no holding entries in this snapshot.

Key Figures

Buy transactions: 0 Sell transactions: 0 Net buy/sell direction: neutral +1 more

4 metrics

Buy transactions 0 buyCount in transactionSummary

Sell transactions 0 sellCount in transactionSummary

Net buy/sell direction neutral netBuySellDirection in transactionSummary

Holding entries 0 holdingEntries in transactionSummary

Key Terms

reportingPersons, transactionSummary, derivativeSummary

3 terms

reportingPersons financial

"reportingPersons includes BioLineRx director Yan Shaoyu"

transactionSummary financial

"transactionSummary aggregates counts for buys, sells, and other actions"

derivativeSummary financial

"derivativeSummary is empty, showing no derivative positions"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the BioLineRx (BLRX) Form 3 filing by Yan Shaoyu show?

The Form 3 for BioLineRx director Yan Shaoyu shows an initial insider report with no transactions. Buy, sell, acquire, and dispose counts are all zero, and no holdings or derivative positions are listed in this data snapshot.

Are there any share purchases or sales reported in the BioLineRx (BLRX) Form 3?

No, the BioLineRx Form 3 reports zero buy and zero sell transactions. The transaction summary shows no activity across buy, sell, acquire, dispose, gift, tax withholding, or restructuring categories for this reporting person.

Does the BioLineRx (BLRX) Form 3 show any derivative securities for Yan Shaoyu?

No, the filing’s derivativeSummary is empty for BioLineRx director Yan Shaoyu. The transaction summary also shows a derivativeTransactionCount of zero, indicating no derivative exercises, conversions, or related derivative transactions in this snapshot.

What does the transaction summary in the BioLineRx (BLRX) Form 3 indicate?

The transactionSummary lists netBuySellDirection as neutral, with all buy, sell, acquire, dispose, and exercise counts and share amounts at zero. It also shows no gifts, tax withholding, or restructuring transactions for this reporting person.

Are any holdings reported for Yan Shaoyu in the BioLineRx (BLRX) Form 3?

The Form 3 data shows a holdingEntries value of 0, meaning no specific holdings are itemized in this snapshot. Combined with zero transactions and an empty derivativeSummary, the filing currently provides only the reporter’s identity and role.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Yan Shaoyu

(Last) (First) (Middle)

C/O BIOLINERX LTD.

2 HAMA'AYAN STREET

(Street)

MODII'N 7177871

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioLineRx Ltd. [ BLRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Shaoyu Yan	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)